Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Operating expenses:
Research and development	$ 987	$ 31,893
General and administrative	128	11,109
Total operating expenses	1,115	43,002
Loss from operations	(1,115)	(43,002)
Other expense:
Change in fair value of preferred stock tranche liability	0	(17,030)
Interest income		49
Interest expense		(28)
Total other expense, net		(17,009)
Net loss	$ (1,115)	$ (60,011)
Net loss per common share, basic and diluted	$ (0.12)	$ (3.40)
Weighted average common shares outstanding, basic and diluted	9,625,679	17,665,683